It has also been shown that the GP2 based vaccines are effective in stimulating peptide-specific immunity, especially in CD8+ T cell stimulation with anti-tumor activity in human leukocyte antigen (HLA)-A2 + breast cancer patients[37]. This evidence concerns the gene CD8A and breast carcinoma.